Two Prescient Assets Selected by Doherty Institute as Group 1 Candidate for COVID-19 Antiviral Testing Program

- **Both assets chosen based on potential antiviral qualities**
- **Doherty Institute will conduct testing**
- **New patent applications filed to protect all new intellectual property generated**

MELBOURNE Australia 21 July 2020: Prescient Therapeutics Limited (Prescient; ASX: PTX) today announced it has signed a research agreement with the Peter Doherty Institute for Infection and Immunology (Doherty Institute), a joint venture between the University of Melbourne and the Royal Melbourne Hospital, following selection of two of its existing assets for the Doherty Institute's Testing Program for SARS-CoV-2 Antiviral Drugs Program. Both were assessed as Group 1 priority candidates.

The program guidelines define, Group 1 candidates as having the "highest or strong likelihood of antiviral efficacy – compounds in this grouping will be eligible for Tier 1 laboratory testing."

The Doherty Institute is a centre of excellence of leading scientists, clinicians and researchers dedicated to the prevention, treatment and cure of infectious diseases. The Doherty Institute investigates a wide variety of infectious diseases but has pivoted its expertise towards the COVID-19 response. Notably, the Doherty Institute gained international prominence in the fight against COVID-19 in January 2020 when it became the first centre outside China to grow the SARS-CoV-2 strain in cell culture and share with laboratories across the world.

Antiviral candidates for the testing program were assessed by an independent Scientific Review Panel of experts in virology, antivirals and the clinical trials of antiviral drugs.

Prescient's assets were selected based on a detailed review of available existing data; as well as additional pre-clinical data supporting their rationale for use as anti-viral therapies.

Prescient has already filed new patent applications for both assets for their use as anti- SARS-CoV-2 agents and all additional intellectual property created during the Doherty Institute screening process will be owned by Prescient.

Prescient Therapeutics CEO Steven Yatomi-Clarke said, “While we remain totally focused on advancing our promising anti-cancer clinical pipeline, we are delighted that two of our assets have been selected for this important national effort by some of the world’s leading medical researchers to help address this urgent global health emergency.”

Testing program process, costs and timing

The testing program is a two-step process involving *in-vitro* testing at the Doherty Institute, and potentially *in-vivo* tests in a small animal model. Eligibility for the second stage depends on positive results in the first.

Prescient’s contribution to the study is immaterial, being $70,000 for the testing of both assets in the first instance. Initial results are expected to be available in September and October 2020.

Prescient will provide an update for investors on material developments as information is made available.

– Ends –

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Cell Therapies

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR’s modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens.
OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Cell Therapy: Prescient has several other initiatives underway to develop new cell therapy approaches.

Targeted Therapies

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the only RhoA inhibitor in the world in clinical development. PTX-100 is currently in a PK/PD basket study of hematological and solid malignancies, focusing on cancers with Ras and RhoA mutations. In a previous Phase 1 trial in advanced solid tumours, PTX-100 was well tolerated and achieved stable disease.

PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound has encouraging Phase 2a data in HER2-negative breast cancer; Phase 1b/2 in relapsed and refractory AML and Phase 1b in recurrent or persistent platinum resistant ovarian cancer:

COVID-19 Therapies

Two assets are being assessed by the Doherty Institute for antiviral activity against SARS-CoV-2, the virus that causes COVID-19 disease.

Find out more at ptxtherapeutics.com, or connect with us via Twitter @PTX_AUS and LinkedIn.

The Board of Prescient Therapeutics Limited have approved the release of this announcement.

For more information please contact:

Steven Yatomi-Clarke CEO & Managing Director Prescient Therapeutics steven@ptxtherapeutics.com	**Investor enquiries:** Warrick Lace – Reach Markets +61 404 656 408 warrick.lace@reachmarkets.com.au	**Media enquiries:** Andrew Geddes – CityPR +61 2 9267 4511 ageddes@citypublicrelations.com.au

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other

factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Supplemental COVID-19 Risk Factors

Please see our website : Supplemental COVID-19 Risk Factors